Clinical Trials on Episiotomy Extended by Laceration in New Zealand

Total 4 results

TransThera Sciences (Nanjing), Inc.

Completed

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Fusion | FGFR1 Alteration | FGFR3 Alteration

United States
Montefiore Medical Center
Columbia University

Terminated

Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge

Breast Discharge Infected | Intraductal Papilloma of Breast

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Available

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Breast Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Colon Cancer | Medullary Thyroid Cancer | Papillary Thyroid Cancer | Other Solid Tumors With Evidence of Activating RET Alteration

Spain, United States, Australia, France, Germany, Israel, Italy, Japan, New Zealand, Poland, Singapore, Switzerland
Tyra Biosciences, Inc

Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)

Solid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditions

Australia, United States, France, Spain

Clinical Trials on Episiotomy Extended by Laceration in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations